Advanced search
Publication Cover
Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration Volume 20, 2019 - Issue 5-6
Submit an article Journal homepage
3,730
Views
15
CrossRef citations to date
0
Altmetric
Research Article

Post-hoc analyses of the edaravone clinical trials Study 16 and Study 19: a step toward more efficient clinical trial designs in amyotrophic lateral sclerosis

Joseph M. PalumboMitsubishi Tanabe Pharma Development America, Jersey City, NJ, USA, ;Mitsubishi Tanabe Pharma Corporation, Tokyo, Japan, View further author information
,
Jean HubbleMitsubishi Tanabe Pharma America, Jersey City, NJ, USA, and View further author information
,
Stephen AppleMitsubishi Tanabe Pharma America, Jersey City, NJ, USA, and View further author information
,
Koji TakeiMitsubishi Tanabe Pharma Corporation, Tokyo, Japan, View further author information
,
Kikumi TsudaMitsubishi Tanabe Pharma Corporation, Tokyo, Japan, View further author information
,
Shawn LiuMitsubishi Tanabe Pharma Development America, Jersey City, NJ, USA, View further author information
,
Jeffrey ZhangPrinceton Pharmatech, Princeton, NJ, USAView further author information
&
Wendy AgneseMitsubishi Tanabe Pharma America, Jersey City, NJ, USA, and View further author information
 show all
Pages 421-431 | Received 28 Sep 2018, Accepted 18 Mar 2019, Published online: 13 Apr 2019

References

  • Brooks BR, Jorgenson JA, Newhouse BJ, Shefner JM, Agnese W. Edaravone in the treatment of amyotrophic lateral sclerosis: efficacy and access to therapy – a roundtable discussion. Am J Manag Care. 2018;24:S175–86.
  • Katyal N, Govindarajan R. Shortcomings in the current amyotrophic lateral sclerosis trials and potential solutions for improvement. Front Neurol. 2017;8:521.
  • Mitsumoto H, Brooks BR, Silani V. Clinical trials in amyotrophic lateral sclerosis: why so many negative trials and how can trials be improved? Lancet Neurol. 2014;13:1127–38.
  • Center for Drug Evaluation and Research (CDER). Guidance for industry: enrichment strategies for clinical trials to support approval of human drugs and biological products. 2012. Available at: https://www.fda.gov/ucm/groups/fdagov-public/@fdagov-drugs-gen/documents/document/ucm332181.pdf. Accessed January 7, 2019.
  • Beydoun SR, Rosenfeld J. Edaravone in amyotrophic lateral sclerosis—lessons from the clinical development program and the importance of a strategic clinical trial design. US Neurol. 2018;14:47–53.
  • Maragakis NJ. What can we learn from the edaravone development program for ALS? Amyotroph Lateral Scler Frontotemporal Degener. 2017;18:98–103.
  • Yoshino H, Kimura A. Investigation of the therapeutic effects of edaravone, a free radical scavenger, on amyotrophic lateral sclerosis (Phase II study). Amyotroph Lateral Scler. 2006;7:241–5.
  • Abe K, Itoyama Y, Sobue G, Tsuji S, Aoki M, Doyu M, et al. Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients. Amyotroph Lateral Scler Frontotemporal Degener. 2014;15:610–7.
  • Writing Group on Behalf of the Edaravone ALS 17 Study Group. Exploratory double-blind, parallel-group, placebo-controlled extension study of edaravone (MCI-186) in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2017;18:20–31.
  • Writing Group on Behalf of the Edaravone ALS 18 Study Group. Exploratory double-blind, parallel-group, placebo-controlled study of edaravone (MCI-186) in amyotrophic lateral sclerosis (Japan ALS severity classification: grade 3, requiring assistance for eating, excretion or ambulation). Amyotroph Lateral Scler Frontotemporal Degener. 2017;18:40–8.
  • Writing Group; Edaravone (MCI-186) ALS 19 Study Group. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2017;16:505–12.
  • Writing Group on Behalf of the Edaravone ALS 19 Study Group. Open-label 24-week extension study of edaravone (MCI-186) in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2017;18:55–63.
  • Edaravone (MCI-186) ALS 16 Study Group. A post-hoc subgroup analysis of outcomes in the first phase III clinical study of edaravone (MCI-186) in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2017;18:11–9.
  • Japan Intractable Diseases Information Center. Amyotrophic lateral sclerosis (ALS) [Japanese]. Available at: http://www.nanbyou.or.jp/entry/214. Accessed July 19, 2018.
  • Atassi N, Berry J, Shui A, Zach N, Sherman A, Sinani E, et al. The PRO-ACT database: design, initial analyses, and predictive features. Neurology. 2014;83:1719–25.
  • Jansen-van der Weide MC, Gaasterland CMW, Roes KCB, Pontes C, Vives R, Sancho A, et al. Rare disease registries: potential applications towards impact on development of new drug treatments. Orphanet J Rare Dis. 2018;13:154.
  • Karam C, Berry JD. Heterogeneity, urgency, generalizability, and enrollment: the HUGE balance in ALS trials. Neurology. 2019;92:215–6.
  • van Eijk RPA, Westeneng HJ, Nikolakopoulos S, Verhagen IE, van Es MA, Eijkemans MJC, et al. Refining eligibility criteria for amyotrophic lateral sclerosis clinical trials. Neurology. 2019;92:e451–e460.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.